Sedation for terminally ill cancer patients
A multicenter retrospective cohort study in South Korea

Young Saing Kim, MD, PhD, Haa-Na Song, MD, Jin Seok Ahn, MD, PhD, Su-Jin Koh, MD, PhD, Jun Ho Ji, MD, In Gyu Hwang, MD, PhD, Jina Yun, MD, PhD, Jung Hye Kwon, MD, PhD, Jung Hun Kang, MD, PhD

Abstract
Sedation therapy is a potential solution to providing relief from refractory symptoms at end of life. The aim of this study was to investigate actual sedation practice and physician characteristics associated with the use of sedation for terminally ill cancer patients in South Korea.

The authors declare that there is no conflict of interest.

1. Introduction
Terminal ill cancer patients commonly exhibit severe physical and psychological symptoms[1-3] and adequate symptom control is the core of palliative care[4,5]. Despite ongoing efforts to alleviate symptoms, physicians occasionally fail to relieve patient suffering[6-9]. Palliative sedation therapy is a potential solution to provide relief from these refractory symptoms. Use of sedation is distinct from Euthanasia[10] and does not hasten death in patients with terminal cancer.[11,12] Several guidelines provide appropriate indications for the use of sedation and detail its clinical implications.[1,13,14]

The rate of use of sedation for patients with terminal cancer varies in western countries from 10% to 66.7% and depends on culture, country, subjects, and care setting.[12,15,16] Although many studies have evaluated sedation practice, few have been undertaken in Asia, where family members tend to be deeply involved in health-care decision making, even if patients are fully competent.[17] Thus, we considered significant differences may exist in the use of sedation therapy. A previous Japanese study reported that palliative sedation was used in 50.3% of patients in a palliative care unit.[18] However, the study sample size (n=124) was too small to assess real practice patterns. Previously, we reported that the sedation rate in dying cancer patients was only 2%,[19] but this study was limited by its single cancer center design and exclusion of episodic use of sedatives for symptom relief.
The aim of the present study was to investigate actual sedation practice in South Korea, including the percentage of sedated patients, type of sedation (continuous or intermittent), drugs, indications, and to identify physician-associated factors related to the use of sedation.

2. Methods

2.1. Patients

We conducted a review of consecutive patients who died of advanced cancer at seven tertiary medical centers in South Korea between January 2010 and October 2015. Computer archived medical records were used to obtain data for the analysis. The use of sedation at end of life was defined as the administration of intravenous or oral sedative medication to relieve intolerable symptoms within the last 2 weeks of life. Sedative agents included benzodiazepines (midazolam, diazepam, lorazepam, and clonazepam), barbiturates (phenobarbital and thiopental), and propofol. The use of sedatives for an endoscopic procedure, insomnia, anxiety, or seizure control was excluded. Sedation was classified as either continuous or intermittent. Continuous sedation involves the uninterrupted use of sedation until death, whereas intermittent sedation is applied for short-term symptomatic relief with return of consciousness in between. This retrospective study was approved by the institutional review board at each participating center. The requirement for informed patient consent was waived because our study posed minimal risk to patients and obtaining consent was impracticable.

2.2. Data collection

Data regarding
(1) clinical characteristics of patients: age, sex, and cancer type,
(2) details of sedation: commencement date, indication for use, specific drugs used, type of sedation, and
(3) physician characteristics: specialty, duration of practice, and affiliation were collected.

Duration of sedation was measured in days from the first dose of sedatives until the time of death.

2.3. Statistical analysis

Descriptive data are presented as numbers (%) or mean (standard deviations). Comparisons of baseline characteristics between sedated patients and non-sedated patients were performed using Student’s t test for continuous variables and the chi-square test for categorical variables. Two-sided P values < .05 were considered statistically significant. The analysis was performed using the Statistical Package for the Social Sciences (SPSS, version 21.0; SPSS Software, IBM Corp., Armonk, NY).

3. Results

3.1. Patient characteristics and sedation rates

A total of 8309 patients were included in the study. Mean patient age was 61.6 (±13.1) years and 62.5% were male. The most common cancer was gastrointestinal (40.5%) followed by lung cancer (24.1%). End of life care was mainly performed by hematology or oncology specialists (91.4%). Overall, 1334 patients (16.1%) received sedation. Sedations rates varied according to cancer type (range, 8.3%–19.4%); the use of sedation was highest with lung cancer. The use of sedation varied according to gender and the area of specialization of the treating physician. Male patients received sedation more often than female patients (16.8% vs. 14.8%, P = .017). Sedation rates were significantly different depending on physician specialty; family physicians used sedation therapy most often (37.6%), followed by hematologists/medical oncologists (13.9%), other internists (10.7%), and surgical oncologists (9.4%). Career duration also influenced the use of sedation, with the highest use by physicians with >5 to 10 years of experience (22.1%) and lowest for those with 5 years or less (10.2%). In addition, the proportion of sedated patients varied markedly between participating institutions (range, 7.0%–49.7%). The characteristics of sedated and non-sedated patients are summarized in Table 1.

3.2. Clinical features of sedation

Indications for sedation included delirium (n = 524, 39.3%), pain (n = 308, 23.1%), dyspnea (n = 292, 21.9%), and other reasons (n = 210, 15.7%) (Table 2). Median duration of sedation from initiation to death was 3 days (range, 1–36 days). Lorazepam was most frequently used for sedation (34.8%), followed by midazolam (28.9%) and diazepam (18.6%). Intermittent sedation until death was used more often than continuous sedation (61.8% vs. 38.2%).

4. Discussion

This study describes current sedation practice in terminal cancer patients in South Korea. To the best of our knowledge, this study included the largest cohort (n = 8309) of terminally ill cancer patients investigated to date. Another strength of the present study is that it encompassed different clinical settings providing end of life care for cancer patients, including inpatient hospice unit and medical oncology, internal medicine, and surgical wards. In South Korea, about 90% of patients die in hospitals, although home is considered to be the ideal place for end of life care. The percentage of patients that received sedation in our cohort was 16.1%, which is lower than previously reported. One of the largest studies on this topic from Austria (n = 2414) reported that 21% of patients in palliative care units received sedation for refractory symptoms. A systematic review of 1807 patients including 10 studies by Maltoni et al[2] reported a sedation rate of 34.4%, but there was a large inter-study variation (range, 14.6%–66.7%).

Our data showed that end of life care in Korean cancer patients is usually provided by medical oncologists who were engaged in active cancer treatment for their patients. Lack of knowledge, negative perceptions towards hospice care, and insufficient facilities hinder referral of terminal cancer patients to specialist palliative care units. As a result, only 14% of terminal cancer patients were estimated to receive hospice and palliative services in South Korea. Interestingly, in the present study, physician background, training, and experience were found to influence decision making regarding sedation therapy at end of life. No clinical practice guidelines on palliative sedation have been issued in Korea, and this lack of a national consensus has resulted in considerable variation in practice among treating physicians. The high rate of sedation (57.6%) practiced by family physicians may be related to the fact that they usually manage cancer patients in the palliative care setting. In contrast, surgical oncologists, who usually provide curative anticancer treatment, used sedation least frequently. These findings demonstrate nation-wide recommen-
Deductions are required to provide physicians with a framework for decision-making and clinical application.

Benzodiazepines are the most commonly used medications for sedation; among the benzodiazepine class of drugs, midazolam is most frequently prescribed and considered a drug of first choice.\[6,24\] Midazolam has advantages over other benzodiazepines because of its rapid onset, short elimination half-life, and easy titration.\[25,26\] In the present study, lorazepam was more often administered than midazolam, and diazepam (another benzodiazepine) was commonly used, which indicates that the choice of drug for palliative sedation also depended on physician experience and preference. Delirium, pain, and dyspnea were the main refractory symptoms that led to the use of sedation. Consistent with previous reports,\[12,21\] delirium was the most common indication for sedation in our study. The median duration of sedation in the present study was 3 days, which is similar to those reported in previous studies.\[6,18,27\]

Our study has several limitations due to its retrospective design. First, we did not acquire detailed information about sedation, including the level of sedation, use of concurrent drugs, drug dosage, family wishes, and decision-making processes. Second, no information was available regarding physician attitude and level of knowledge regarding palliative sedation. To reduce bias, prospective, multicenter studies are required, and a standardized format should be used to record details of sedation practice.

In conclusion, this large cohort study provides insight into the current sedation practice in terminally ill cancer patients in South Korea. It reveals wide variations in the rate of use of sedation that depend on physician background, training, and experience. We recommend the introduction of nation-wide guidelines regarding indications and optimization of palliative sedation and continued education on its use in South Korea.

Table 1

| Variables                      | Total (n = 8309) | Sedated (n = 1334) | Non-sedated (n = 6975) | P value |
|--------------------------------|-----------------|-------------------|-----------------------|---------|
| Age, years                     |                 |                   |                       |         |
| Mean (±SD)                     | 61.6 (±13.1)    | 61.8 (±12.7)      | 61.6 (±13.2)          | .547    |
| Sex                            |                 |                   |                       |         |
| Male                           | 5105            | 872 (16.8%)       | 4233 (63.2%)          | .017    |
| Female                         | 3114            | 462 (14.8%)       | 2652 (85.2%)          |         |
| Primary tumor                  |                 |                   |                       | .001    |
| Gastrintestinal                | 3376            | 622 (18.4%)       | 2754 (81.6%)          |         |
| Lung                           | 2001            | 389 (19.4%)       | 1612 (80.6%)          |         |
| Genitourinary                  | 408             | 69 (16.9%)        | 339 (83.1%)           |         |
| Breast                         | 367             | 62 (16.9%)        | 305 (83.1%)           |         |
| Head and neck                  | 261             | 34 (13.0%)        | 227 (87.0%)           |         |
| Others                         | 1806            | 158 (8.3%)        | 1738 (91.7%)          |         |
| Physician’s specialty          |                 |                   |                       | .001    |
| Hematology/medical oncology    | 7598            | 1056 (13.9%)      | 6542 (86.1%)          |         |
| Internal medicine except H/MO | 215             | 23 (10.7%)        | 192 (89.3%)           |         |
| Family medicine                | 432             | 249 (56.6%)       | 183 (42.4%)           |         |
| Surgery                        | 64              | 6 (9.4%)          | 58 (90.6%)            |         |
| Practice duration of physician†|                 |                   |                       | .001    |
| ≤5 years                       | 461             | 47 (10.2%)        | 414 (89.8%)           |         |
| >5–10 years                    | 2982            | 658 (22.1%)       | 2324 (77.9%)          |         |
| >10–15 years                   | 1645            | 237 (14.4%)       | 1408 (85.6%)          |         |
| >15 years                      | 3189            | 392 (12.3%)       | 2797 (87.7%)          |         |
| Institution                    |                 |                   |                       | .001    |
| A                              | 2211            | 207 (9.4%)        | 2004 (90.6%)          |         |
| B                              | 2700            | 189 (7.0%)        | 2511 (93.0%)          |         |
| C                              | 731             | 88 (12.0%)        | 643 (88.0%)           |         |
| D                              | 789             | 164 (20.8%)       | 625 (79.2%)           |         |
| E                              | 338             | 126 (37.3%)       | 212 (62.7%)           |         |
| F                              | 539             | 268 (49.7%)       | 271 (50.3%)           |         |
| G                              | 1001            | 292 (29.2%)       | 709 (70.8%)           |         |

H = hematology, MO = medical oncology, SD = standard deviation.

* Others include hepatobiliary cancers (n = 1048), gynecologic cancer (n = 241), hematologic malignancies (n = 232), cancer of unknown primary site (n = 99), soft tissue sarcomas (n = 84), skin cancers (n = 51), primary bone cancers (n = 36), primary central nervous system tumors (n = 35), thyroid cancer (n = 21), neuroendocrine tumors (n = 16), and unspecified (n = 32).

† Information about the practice duration of physician was not available in 32 patients.

Table 2

Sedation characteristics.

| Characteristics | No. (%) |
|-----------------|---------|
| Indication      |         |
| Delirium        | 524 (39.3%) |
| Pain            | 308 (23.1%) |
| Dyspnea         | 292 (21.9%) |
| Others          | 210 (15.7%) |
| Duration (days) |         |
| Median          | 3       |
| Range           | 1–36    |
| Sedative drugs  |         |
| Lorazepam       | 438 (32.8%) |
| Midazolam       | 385 (28.9%) |
| Diazepam        | 248 (18.6%) |
| Propofol        | 1 (0.1%)  |
| Others          | 262 (19.6%) |
| Types           |         |
| Intermittent    | 825 (61.8%) |
| Continuous      | 509 (38.2%) |
Author contributions

Conceptualization: Jin Seok Ahn, Jung Hye Kwon, Jung Hun Kang.

Data curation: Young Saing Kim, Haa-Na Song, Su-Jin Koh, Jun Ho Ji, In Gyu Hwang, Jina Yun.

Formal analysis: Young Saing Kim.

Investigation: In Gyu Hwang, Jina Yun.

Methodology: Su-Jin Koh, Jina Yun, Jung Hun Kang.

Resources: Jin Seok Ahn.

Supervision: Jin Seok Ahn, Jung Hun Kang.

Writing – original draft: Young Saing Kim, Haa-Na Song.

Writing – review & editing: Young Saing Kim, Jung Hun Kang.

Young Saing Kim orcid: 0000-0003-0207-2617.

References

[1] Cherny NI. ESMO Guidelines Working GroupESMO Clinical Practice Guidelines for the management of refractory symptoms at the end of life and the use of palliative sedation. Ann Oncol 2014;25(Suppl 3): ii143–52.

[2] Barbera L, Seow H, Howell D, et al. Symptom burden and performance status in a population-based cohort of ambulatory cancer patients. Cancer 2010;116:5767–76.

[3] Baker TA, Krok-Schoen JL, McMillan SC. Identifying factors of psychological distress on the experience of pain and symptom management among cancer patients. BMC Psychol 2016;4:52.

[4] Grunberg SM. New directions in supportive care. Support Care Cancer 2005;13:135–7.

[5] Tai SY, Lee CY, Wu CY, et al. Symptom severity of patients with advanced cancer in palliative care unit: longitudinal assessments of symptoms improvement. BMC Palliat Care 2016;15:32.

[6] Beller EM, van Driel ML, McGregor L, et al. Palliative pharmacological sedation for terminally ill adults. Cochrane Database Syst Rev 2015;1:CD010206.

[7] Claessens P, Menten J, Schotsmans P, et al. Palliative sedation: a review of the research literature. J Pain Symptom Manage 2008;36:310–33.

[8] Anquinet L, Rietjens J, van der Heide A, et al. Physicians’ experiences and perspectives regarding the use of continuous sedation until death for cancer patients in the context of psychological and existential suffering at the end of life. Psychooncology 2014;23:539–46.

[9] Morita T, Imai K, Yokomichi N, et al. Continuous deep sedation: a proposal for performing more rigorous empirical research. J Pain Symptom Manage 2017;53:146–52.

[10] ten Have H, Welie JV. Palliative sedation versus euthanasia: an ethical assessment. J Pain Symptom Manage 2014;47:123–36.

[11] Maeda I, Morita T, Yamaguchi T, et al. Effect of continuous deep sedation on survival in patients with advanced cancer (J-PROVAL): a propensity score-weighted analysis of a prospective cohort study. Lancet Oncol 2016;17:115–22.

[12] Maltoni M, Scarpi E, Rosati M, et al. Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol 2012;30:1378–83.

[13] Gurschick I, Mayer DK, Hanson LC. Palliative sedation: an analysis of international guidelines and position statements. Am J Hosp Palliat Care 2015;32:660–71.

[14] Abarshi E, Rietjens J, Caraceni A, et al. Towards a standardised approach for evaluating guidelines and guidance documents on palliative sedation: study protocol. BMC Palliat Care 2014;13:34.

[15] Quill TE, Lo B, Brock DW. Palliative options of last resort: a comparison of voluntarily stopping eating and drinking, terminal sedation, physician-assisted suicide, and voluntary active euthanasia. JAMA 1997;278:2099–104.

[16] Maltoni M, Scarpi E, Nanni O. Palliative sedation in end-of-life care. Curr Opin Oncol 2013;25:360–7.

[17] Lee SK, Knobf MT. Family involvement for breast cancer decision making among Chinese-American women. Psychooncology 2016;25:1493–9.

[18] Kohara H, Ueoka H, Takeyama H, et al. Sedation for terminally ill patients with cancer with uncontrollable physical distress. J Palliat Med 2005;8:20–5.

[19] Haa Na S, An Na L, Un Suk L, et al. Palliative sedation: experience in a Tertiary Center in Korea. Korean J Med 2013;2013:267.

[20] Cohen J, Provdoc I, Miccinesi G, et al. International study of the place of death of people with cancer: a population-level comparison of 14 countries across 4 continents using death certificate data. Br J Cancer 2015;113:1397–404.

[21] Schur S, Weixler D, Gabl C, et al. Sedation at the end of life—a nationwide study in palliative care units in Austria. BMC Palliat Care 2016;15:50.

[22] Jho HJ, Chang YJ, Song HY, et al. Perceived timeliness of referral to hospice palliative care among bereaved family members in Korea. Support Care Cancer 2015;23:2805–11.

[23] Shim HY, Chang YJ, Kawk KS, et al. Do Korean doctors think a palliative consultation team would be helpful to their terminal cancer patients? Cancer Res Treat 2017;49:437–45.

[24] de Graeff A, Dean M. Palliative sedation therapy in the last weeks of life: a literature review and recommendations for standards. J Palliat Med 2007;10:67–85.

[25] Dean MM, Cellarius V, Henry B, et al. Framework for continuous palliative sedation therapy in Canada. J Palliat Med 2012;15:870–9.

[26] Nogueira FL, Sakata RK. Palliative sedation of terminally ill patients. Rev Bras Anestesiol 2012;62:580–92.

[27] Maltoni M, Pinturreri C, Scarpi E, et al. Palliative sedation therapy does not hasten death: results from a prospective multicenter study. Ann Oncol 2009;20:1163–9.